This HTML5 document contains 187 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n10http://dx.doi.org/10.18632/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q55059834
rdf:type
wikibase:Item
schema:description
επιστημονικό άρθρο artikull shkencor 2018年学术文章 2018年学术文章 2018年學術文章 wissenschaftlicher Artikel tudományos cikk บทความทางวิทยาศาสตร์ article científic artículo científico publicado en 2018 artículu científicu 2018年学术文章 teaduslik artikkel 2018 nî lūn-bûn scienca artikolo 2018年學術文章 ২০১৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ article scientific სამეცნიერო სტატია artigo científico (publicado na 2018) научни чланак 2018년 논문 2018年學術文章 vitskapeleg artikkel vědecký článek vetenskaplig artikel գիտական հոդված articolo scientifico artykuł naukowy 2018年の論文 bài báo khoa học научная статья مقالهٔ علمی 2018年學術文章 scientific article vitenskapelig artikkel wetenschappelijk artikel artigo científico (publicado na 2018) מאמר מדעי artikulong pang-agham мақолаи илмӣ 2018年学术文章 tieteellinen artikkeli мақолаи илмӣ 2018年學術文章 سائنسی مضمون naučni članak vedecký článok articol științific article scientifique (publié 2018) videnskabelig artikel (udgivet 2018) 2018年学术文章 научни чланак наукова стаття, опублікована в травні 2018 mokslinis straipsnis artigo científico 2018年學術文章 bilimsel makale научна статия مقالة علمية
p:P577
wds:Q55059834-50BBAE29-0A57-46EB-B6F0-3B5FA8C5A508
wdt:P577
2018-05-08T00:00:00Z
p:P407
wds:Q55059834-8FFF6E5D-F2AB-4A80-BE20-9A1279C36EA1
wdt:P407
wd:Q1860
p:P2860
wds:Q55059834-E6169940-E7DA-455B-9524-2AD1D85D0EE9 wds:Q55059834-E63E806A-37CA-4122-85EA-C9E2B6C5AB3F wds:Q55059834-ED390007-C642-4AEE-8264-7E3A3275763E wds:Q55059834-F4991A02-D548-426A-860E-B46E63D69C5C wds:Q55059834-E3C0AFAA-6819-40FE-A8B3-89CDDF7D8CB8 wds:Q55059834-1B5D01AD-E5C3-45A0-8DD4-029B3F9CB556 wds:Q55059834-24B7DE0F-A111-4DFC-B147-78094914B9C2 wds:Q55059834-2B2BE393-1E3C-47F9-B483-BB5F2F5A3FE7 wds:Q55059834-152B5F0F-9D8F-4B69-BF2F-3214F17E3B2A wds:Q55059834-180679FE-FCBA-47D6-9C2A-0CF75B7CECC4 wds:Q55059834-0453BF3D-92C2-4D31-AC70-25DEC24776FB wds:Q55059834-146225FC-4D82-4048-B239-2740D1307DBE wds:Q55059834-010C8D9C-51BC-42BF-BB71-95C9AC4708D9 wds:Q55059834-92E11A66-9B29-4C86-B788-A7DBD99EAD15 wds:Q55059834-C262A965-B7B6-4089-B097-D6ADDE1855E1 wds:Q55059834-C2BA1777-A9B2-4D3D-9EAE-558E409EBA50 wds:Q55059834-8684C117-A5F3-42CF-82D4-EC6BD00BD231 wds:Q55059834-7C58D334-A376-44CE-81CE-73C9CC1C0509 wds:Q55059834-866E2407-BD2C-41E5-ADCD-0676F52B7B7C wds:Q55059834-71477F6F-CC23-44E3-9120-C002DAFC95D7 wds:Q55059834-63FF397B-F56B-4530-A89B-23CC312BD70B wds:Q55059834-683966AF-DC34-4888-916E-1954500FCAF4 wds:Q55059834-58989F56-B522-4F04-AC35-4F0FA0058002 wds:Q55059834-50945E80-75D5-4A84-A569-B361FCE1EFF4
wdt:P2860
wd:Q43150353 wd:Q34118771 wd:Q38764659 wd:Q54590490 wd:Q36306137 wd:Q35750964 wd:Q44764564 wd:Q43246777 wd:Q35851822 wd:Q46052750 wd:Q42046604 wd:Q37732036 wd:Q30487339 wd:Q35953355 wd:Q34241661 wd:Q33362778 wd:Q26740278 wd:Q42146660 wd:Q40200955 wd:Q74198916 wd:Q35776992 wd:Q38924228 wd:Q35949372 wd:Q39232071
p:P2093
wds:Q55059834-F9F8F52F-BAF8-4601-B17D-CB1EF08D954E wds:Q55059834-FD5C8ADE-6F86-46FF-A127-E9E388E1780D wds:Q55059834-F8A6F817-3D9A-443D-9E43-15CD0116974F wds:Q55059834-F9D928D2-5DBB-4101-8999-AE3D749F6384 wds:Q55059834-FE2BB828-A259-437D-B8A0-D59B8DFC2C04 wds:Q55059834-FE89F069-AC92-4C19-8C8D-903AD967A23B wds:Q55059834-D3AFC84B-0A6A-4AAA-99A8-8C7BDE411C9B wds:Q55059834-632A3BAB-C718-48C7-AA0A-7C9729824D92 wds:Q55059834-444F437D-1FF2-4F92-9549-52E83C96843A wds:Q55059834-48F3F827-C021-42E0-B24B-5854A9057B0D wds:Q55059834-46C52BC4-4894-4601-9119-502F3CBF112B wds:Q55059834-47D6C20E-9956-4DCB-9F6A-14D06CA5A25C wds:Q55059834-9047DB8D-9E59-422E-BC8F-E63C01EFB75D wds:Q55059834-8D735558-FE00-420D-A296-FEC944E60A60 wds:Q55059834-717C0444-1731-4CAA-AA8D-B05C5DAB009C wds:Q55059834-776D5C1D-45AE-4FF6-AD51-3A8D8DCD372F wds:Q55059834-856F2D95-8A33-4469-B8DA-1BD0DFEB6D81 wds:Q55059834-824B4C9E-1B00-45BE-9AB0-77DDD813FB74 wds:Q55059834-18D9FD98-3B55-46D8-84B8-6297580C5E3B wds:Q55059834-2C160597-568D-4A5F-A398-53B1BA0FDAC3 wds:Q55059834-0E857D19-90CE-46BB-B028-24D401BFDE07 wds:Q55059834-08934CD4-E569-4412-9D80-7AA186E78842
wdt:P2093
Jean-Claude Vedovato Lotfi Benboubker Christophe Le Tourneau Paul Franques Lionel Karlin Florence Sabirou Valentine Richez Mariya Pavlyuk Guillemette Fouquet Pierre Ferre Michel Attal Margaret Macro Monia Ouali Niels Moya Stéphanie Guidez Cécile Gruchet Anne-Marie Stoppa Anthony Levy Xavier Leleu Hélène Gardeney Thomas Syshenko Arthur Bobin
rdfs:label
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
skos:prefLabel
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
schema:name
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
p:P50
wds:Q55059834-31045230-EEC9-48E1-B29E-80337880FC34
wdt:P50
wd:Q85789960
p:P1476
wds:Q55059834-14FD142E-2C1E-44E4-BA0C-276CE9D61171
wdt:P1476
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
p:P304
wds:Q55059834-C606EFAB-3FDF-49D3-9F32-4399147319AA
wdt:P304
23890-23899
p:P31
wds:Q55059834-4696CBFD-9AF4-4F19-B9C8-5971F06414DC
wdt:P31
wd:Q13442814
p:P921
wds:Q55059834-A9BC7513-EA16-43C8-A486-3942BF92D438
wdt:P921
wd:Q422252
p:P698
wds:Q55059834-6A942993-71F3-4A3F-B961-404A11A94C0D
wdtn:P698
n11:29844860
wdt:P698
29844860
p:P1433
wds:Q55059834-6D88DF73-65EF-4CEE-A216-58D3597EB015
wdt:P1433
wd:Q1573155
p:P433
wds:Q55059834-6075388F-516C-4086-8264-74E36CA5A3B7
p:P478
wds:Q55059834-5300167B-D319-4B46-86F8-370E2A7EAD26
wdt:P433
35
wdt:P478
9
p:P356
wds:Q55059834-36D1F189-47C8-4EF7-877D-7D2D326697F2
wdtn:P356
n10:ONCOTARGET.25156
wdt:P356
10.18632/ONCOTARGET.25156
p:P932
wds:Q55059834-E4014A29-86C3-4E6C-A178-2AF06D2FBED3
wdt:P932
5963612